Recommendations on prevention of infections in patients with T-cell lymphomas: a narrative review and synthesis

Abstract

T/Natural killer (NK) cell lymphomas (TCL) represent a heterogenous subgroup of non-Hodgkin lymphoma, associated with poorer prognosis and higher treatment toxicity. A cohesive synthesis of infection outcomes among TCL patients is lacking. International guidelines offer no specific recommendations regarding prophylaxis or supportive infection care for TCL patients. This systematic narrative review highlights infection outcomes in TCL patients treated with conventional, and novel therapies. Recommendations for infection screening, antimicrobial prophylaxis and vaccination strategies are outined.

Keywords:

• T cell lymphoma
• infectious complications
• neoplasia
• novel therapies

Disclosure statement

No potential conflict of interest was reported by the author(s). GR and KT have no COI to declare. MAA is an employee of the Walter and Eliza Hall institute and receives milestone payments in relation to venetoclax, to which she is entiteld to a share, as well as honoraria from Abbvie, Janssen, AstraZeneca, Gilead, Novartis, CSL, Takeda. BWT has received grants from MSD, Seqirus and Sanofi, as well as honoraria (paid to institution) from Alexxion, Pfizer, Gilead. MAS has received grants from NHMRC, Merck and F2G, consulting fees from Pfizer, Takeda, Gilead and Merck, honoraria from Pfizer and F2G, participates on the advisory board for Roche and Pfizer, and leads the Australian Society of Infectious Diseases Immunocompromised Host Special Interest Group.

Additional information

Funding

Gemma is supported by NHMRC PhD scholarship #2013970.